The antibody works by targeting a natural defense mechanism that cancer tumors exploit.

Cells in the body essentially use a home security system that relies on certain proteins to protect the cell surface and keep it safe. These proteins help the cell avoid injury and even death from unwanted activation of the immune system.

In a paper published online May 5 in Cell Reports, the Duke team describes the workings of a cancer-fighting antibody they discovered, developed and tested in cell lines and animal models. The antibody dismantles a specific part of a cancer cell's defense system and then employs several mechanisms of attack.

"This is the first completely human-derived antibody developed as an anti-cancer therapy, which is very different from other immunotherapy approaches," said senior author Edward F. Patz, Jr., M.D., the James and Alice Chen Professor of Radiology and professor in the Department of Pharmacology and Cancer Biology at Duke.

Patz and colleagues — including principals from the Duke Human Vaccine Institute who have been advancing the development of antibodies for an HIV vaccine — started with the observation that some lung cancer patients have early-stage tumors that never progress to advanced disease. (Photo via Duke Medicine)

One of the features that separated these patients from those who had more lethal tumors was the presence of antibodies against a protein called complement factor H, or CFH, which protects cells from an immune system attack.

CFH works by preventing activation of an important immune response. It inhibits the deposit of a complement C3b protein on the cell surface. Complement C3b initiates the degradation of the cell membrane, which eventually leads to cell death.

Once the antibody for CFH was identified, Patz and colleagues sought to explore how this immune response could be optimized as a cancer therapy. Critical to that effort was finding a way to produce antibodies that recognized the exact same part of CFH as the autoantibodies made by the early-stage cancer patients, thus assuring that the antibodies would have a particular affinity for cancer cells.

Patz and colleagues pooled the white blood cells from CFH antibody-producing cancer patients and then isolated and cloned the antibody genes from single immune cells that make the specific antibodies.

This was an efficient process that enabled the researchers to produce mature antibodies that recognized the same region of CFH targeted by the original patient's immune systems — therefore leading to the attack of cancer cells, not healthy cells.

The researchers then tested the antibodies in multiple cancer cell lines, including lung, gastric and breast cancers in lab dishes, and in tumors in living mice. They found that the antibodies caused tumor cell death without any obvious side effects. The antibodies also appeared to trigger an additional adaptive immune response when the damaged cells sent signals to recruit an army of lymphocytes, creating a potentially more lethal systemic attack.

"We believe it might be this additional cellular response that could potentially have the most profound impact on cancer outcomes long-term," Patz said, noting that further tests would be required to understand the full potential of the approach.

"This could represent a whole new approach to treating cancer, and it's exciting because the antibody selectively kills tumor cells, so we don't have significant side effects to achieve tumor control," Patz said. "We believe we can modulate the immune response and let the body's own immune system take over to either kill the tumor or keep it from growing."

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Ex-Hamas Wife Whose Father Helped Create the Terrorist Group Meets Jesus in a Miraculous Dream

Gym in Los Angeles Revokes Membership of Woman Who Opposed Man in Women's Locker Room

American Consumers Footing the Bill: Supreme Court Hears Arguments on Trump's Tariff Power

These Two Officials Would Make an Unstoppable Presidential Ticket, Trump Says

High Stakes on the High Seas as US, China Test Limits of Military Power

FAA Slashes Flights at 40 Airports as Democrat Shutdown Grounds America

NYC's First Muslim, Socialist Mayor the Top Story as Democrats Sweep the Off-Term Elections

Dems Win in VA with First Female Governor, Jones Overcomes Murder Text Scandal to Win AG

Texas Voters Approve Requiring Judges to Deny Bail for Certain Violent Felony Charges

Hamas Returns Remains of Last American Hostage; US Proposes 'Stabilization Force' for Post-War Gaza

Parent Groups Demand 50-State Audit to Eliminate DEI in Schools [WATCH]

UPS Plane Crashes and Explodes at a Kentucky Airport, Leaving at Least 9 Dead and Others Missing

Former VP Dick Cheney Dead at 84

Make-or-Break Decision Coming: President Trump's Tariffs on Trial

'Revival on Halloween Night': Hundreds Worship Jesus as Baptisms Unfold in Streets of Baton Rouge

Canadian MP: Reciting 'Hateful' Bible Verses About Homosexuality In Public Should Be Illegal

Canada's Supreme Court Rules 1-Year Minimum Jail Sentence for Child Porn Possession 'Unconstitutional'

The New York Times Exposed a Trafficking Crisis. But Refuses to Name the Men Responsible

Google Caught Hiding Elon Musk's New Grokipedia, Instead Promotes Leftist Wikipedia

How Trump Killed a UN 'Global Green Tax' that Would Have 'Devastated' at the 11th Hour: Breitbart Exclusive